… Patients with stable HFpEF, New York Heart Association functional classes II and III, previous
treatment with β-blockers… (arm B: n = 26) β-blocker treatment and were then crossed over to …

… heart failure, to include patients with heart failure with mid‐range ejection fraction (LVEF 40%
to 49%; HFmrEF). It is possible that heart failure patients … one in seven patients with HFpEF …

… The aim of this study was to clarify the effect of β-blockers (BBs) on respiratory function and
survival in patients with chronic obstructive pulmonary disease with cardiovascular disease (…

… Importantly, from early to late phases, hypertension and related diseases and conditions
such as heart failure (HF), ischemic heart disease, obesity, or obstructive sleep apnea are …

… a foundational therapy for patients with heart failure and a reduced ejection fraction if the
treatment has been shown in large-scale clinical trials to (i) reduce cardiovascular death and/or …

… Treatment of patients with heart failure (HF) and a reduced ejection fraction (HFrEF) is …
reflected in the European Society of Cardiology/Heart Failure Association (ESC/HFA) guidelines, …

… HF with sub-optimal treatment, eg MRA and beta-blocker treatment prior to RASi initiation,
could be present. Patients who were switched from ACEi and ARBs to ARNI, around 6% of …

… caution is required in patients hospitalized for decompensated heart failure. β-Blocker therapy
should only be initiated in the hospital after intravenous therapy has been discontinued for …

… Heart Failure Association on SGLT2 inhibitors in heart failure, … of heart failure hospitalization
and cardiovascular death in … patients already receiving guideline-directed medical therapy, …

… , we aim to provide an insight into the pathophysiology of hypertensive heart disease and to
summarize the current evidence relating to BP control in the prevention and treatment of HF. …